Trial Profile

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Ipatasertib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
Indications Early breast cancer; Male breast cancer; Triple negative breast cancer
Focus Pharmacodynamics
Acronyms BIS-Program

Most Recent Events

16 Apr 2024 The protocol has been amended to change in Arm size from 6 to 4 with drug ratio.
16 Apr 2024 Planned number of patients changed from 210 to 185.
16 Apr 2024 Planned End Date changed from 1 Feb 2025 to 1 Feb 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com